The Who, What, and Where for SGLT2 Inhibitors in Diabetes
October 22, 2020 | 10:30 AM - 12:30 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
Clinical Practice Session
The Who, What, and Where for SGLT2 Inhibitors in Diabetes
October 22, 2020 | 10:30 AM - 12:30 PM
Location: Live-Streamed
Session Description
Recent clinical trials show sodium-glucose cotransporter 2 (SGLT2) inhibitors have a significant effect on reducing risk of progressive renal decline as well as cardiovascular outcomes. These discoveries are changing the existing clinical protocols and leading to new, more effective interventions to care for patients with diabetes. In this session, experts in the field present the current trial results and discuss their clinical implications.
Learning Objective(s)
- Describe the mechanisms of SGLT2
- Discuss the controversies regarding whom SGLT2 mechanisms may not benefit
- Summarize efficacy data for SGLT2 inhibitors on heart failure and related outcomes, the proposed mechanisms of this benefit, and the heterogeneity of effects on heart failure stratified by underlying diabetic kidney disease
- Explain how potential adverse effects of SGLT2 inhibitors can be managed
- Define strategies to optimize concurrent management of diabetes, kidney diseases, and heart disease
Learning Pathway(s)
- Diabetes and Metabolism
- Chronic Kidney Disease
Moderators
- Ian H. de Boer, MD, MS
- Adeera Levin, MD
Presentations
-
Kidney Protection with SGLT2 Inhibitors in Diabetes: Is It for Everyone?
10:30 AM - 11:00 AM
David Cherney, MD, PhD
Kidney Protection with SGLT2 Inhibitors in Diabetes: Is It for Everyone?
October 22, 2020 | 10:30 AM - 11:00 AM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
-
SGLT2 Inhibition for the Deadly Dyad of Diabetes: Heart Failure and Kidney Disease
11:00 AM - 11:30 AM
Matthew Cavender, MD, MPH
Matthew Cavender, MD, MPH
SGLT2 Inhibition for the Deadly Dyad of Diabetes: Heart Failure and Kidney Disease
October 22, 2020 | 11:00 AM - 11:30 AM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
-
Adverse Effects of SGLT2 Inhibition in Advanced Diabetic Kidney Disease and How to Minimize Them
11:30 AM - 12:00 PM
Meg J. Jardine, MBBS, PhD
Meg J. Jardine, MBBS, PhD
A/Professor Meg Jardine is a Program Head of Innovation & Kidney Research at The George Institute and a practising nephrologist. Her research focus is the improvement of clinical outcomes for people with kidney disease and diabetes. Her interests include the integration of clinical care and research endeavours, and the promotion of learning health system principles to contribute to the efficient delivery. She has experience in the design and conduct of national and international trials and is particularly interested in response-adaptive techniques as a solution to many of the challenges facing nephrology trials.
A/Prof Jardine is an Executive Committee member of the international nephrology guidelines body, KDIGO, and has contributed to Australian CARI guideline development. She contributes to policy setting and implementation through roles such as Board Member of the Kidney Health Initiative, a public-private collaboration of the American Society of Nephrology and the US FDA. Her advocacy for the kidney disease trial endeavour is pursued through roles in the AKTN, the International Society of Nephrology Advancing Clinical Trials (ISN-ACTS) core committee and the ANZSN Research Advisory Committee.
Adverse Effects of SGLT2 Inhibition in Advanced Diabetic Kidney Disease and How to Minimize Them
October 22, 2020 | 11:30 AM - 12:00 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
-
Treating the Whole Person with Diabetic Kidney Disease: New Clinical Protocols
12:00 PM - 12:30 PM
Katherine R. Tuttle, MD, FASN
Katherine R. Tuttle, MD, FASN
Treating the Whole Person with Diabetic Kidney Disease: New Clinical Protocols
October 22, 2020 | 12:00 PM - 12:30 PM
Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.
